• Explore /
  • Poster
  • / An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).

An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).

Abstract Poster

Authors

null

Neeta DSouza

Memorial Sloan Kettering Cancer Center, New York, NY

Neeta DSouza , Christopher Gaffney , Christian Hernandez , Patricia Moran , Kara Worth , Melissa McCarter , Manuel R. de Jesus , David B. Solit , Judy Sarungbam , Hikmat A. Al-Ahmadie , Bernard H. Bochner , Gopa Iyer , Jonathan E. Rosenberg , Eugene J. Pietzak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04917809

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4614)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4614

Abstract #

TPS4614

Poster Bd #

99b

Abstract Disclosures

Similar Posters

First Author: Christopher Gaffney

Poster

2021 Genitourinary Cancers Symposium

Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (<span>NMIBC)</span>?

Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (NMIBC)?

First Author: Sarah Prattley

First Author: Gary D. Steinberg

First Author: Karim Chamie